OptiBiotix Health PLC (AIM:OPTI, OTCQB:OPTBF) chief executive Stephen O’Hara talked with Proactive's Stephen Gunnion about the company’s growing exposure to the weight management and gut health markets, highlighting rising global demand for its SlimBiome product and the strategic importance of its US expansion.
O’Hara explained that OptiBiotix Health is a microbiome company focused on developing products that address unmet healthcare needs rather than selling science alone. One of the company’s flagship products, SlimBiome, is a patented ingredient designed to reduce hunger and food cravings, helping consumers eat less and manage weight more effectively. He noted that SlimBiome has won multiple awards and is already sold globally, with a recent US launch through Hydroxycut Hunger Control, an extension of America’s leading weight management brand.
Discussing recent commercial momentum, O’Hara pointed to a substantial 24-metric-tonne order from Meelung Trading in Taiwan, which he said reflects accelerating demand across Asia. He linked this growth to increased interest in alternatives to GLP-1 drugs such as Ozempic and semaglutide, explaining that some consumers prefer not to take drugs, cannot afford them, or are seeking weight maintenance solutions after stopping medication. As O’Hara put it, “this is a big market… worth $1.2 billion in 2024 and growing about 17% per year.”
The interview also covered OptiBiotix Health’s broader product platform, including WellBiome for gut health, SweetBiotix as a sweet fibre, and longer-term microbiome modulators. O’Hara additionally outlined the rationale for the company joining the OTCQB market last year, which increases accessibility and liquidity for US investors at a time of growing awareness of the microbiome sector in the US.
For more insights from company leaders, visit Proactive’s YouTube channel, and don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future updates.
#OptiBiotix #OptiBiotixHealth #SlimBiome #GLP1 #WeightManagement #GutHealth #Microbiome #HealthSupplements #AntiObesity #AIMStocks #OTCQB #USExpansion #InvestorInterview #ProactiveInvestors
